Keywords: antibacterial, pipeline, represemts, 3b, potential, sales, launches
Antibacterial pipeline represemts $3B potential sales by 2015
Article | 08 January 2007
Launches of premium-priced glycopeptides from Pfizer, Theravance/Astellas and Targanta, as well as next-generation cephalosporins from Johnson & Johnson/Basilea and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
